Myocardial Infarction News and Research

RSS

People with gum disease are more likely to suffer from atherosclerosis

A new study by researchers at Columbia University Medical Center provides the most direct evidence to date that preventing gum disease could significantly improve your chances of avoiding vascular problems.

7 Feb 2005

Drug reviparin reduces the risk of death after heart attack

The drug reviparin (a low molecular weight heparin anticoagulant), when administered to patients with a heart attack, is effective in reducing the risk of death and the risk of a subsequent heart attack, according to a study in the January 26 issue of JAMA.

26 Jan 2005

Vioxx could have caused 140000 excess cases of coronary heart disease in the USA since 1999

The arthritis drug Vioxx could have caused an estimated 88 000–140 000 excess cases of serious coronary heart disease in the USA since its launch in 1999, concludes a study published online by The Lancet.

24 Jan 2005

Medicine alone may not offer best quality of life for patients with moderate heart attack risk

Routine angiography and revascularization procedures, if indicated, appear to offer better quality of life than conservative medical treatment for patients with chest pain and evidence of coronary artery disease, according to a new study (PDF file) in the Jan. 18, 2005 issue of the Journal of the American College of Cardiology.

19 Jan 2005

Statins lower C-reactive protein (CRP), a major new risk factor for heart disease marked by inflammation

For years, doctors have believed that statin therapy lowers the risk of heart disease solely by lowering levels of cholesterol.

9 Jan 2005

Stem cells from umbilical cord blood effectively treated heart attacks

When injected into rats' hearts soon after a heart attack, stem cells taken from human umbilical cord blood (HUCB) greatly reduced the size of heart damage and restored pumping function to near normal. This improvement occurred without the need for drugs to prevent the rats' immune system from rejecting the human cells.

5 Jan 2005

Arthritis drug caution advised by New Zealand experts

An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.

21 Dec 2004

Biological clock affects the patterns of heart-rate control in healthy individuals

In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston’s Brigham and Women’s Hospital (BWH) have found that the body’s biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.

21 Dec 2004

Aspirin overlooked as an effective and inexpensive means to reduce cardiovascular disease risk in diabetic women and young adults

Cardiovascular disease risk is extremely high in adults with diabetes. Yet women as well as people under 50 who have diabetes do not use aspirin, despite the fact that aspirin has been found an effective and inexpensive means to reduce risk of first and subsequent heart attack.

20 Dec 2004

Risk of having a heart attack is elevated in the weeks after stopping use of nonsteroidal anti-inflammatory drugs

The risk of having a heart attack is elevated in the weeks after stopping use of nonsteroidal anti-inflammatory drugs, according to an article in the December issue of The Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Dec 2004

Landmark revascularization procedure

The People's Hospital of Beijing University performed a combined revascularization procedure utilizing beating heart bypass surgery, along with transmyocardial revascularization and stem cell implantation.

13 Dec 2004

Greater risk of heart attack associated with Vioxx than Celebrex

In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.

8 Dec 2004

Acetaminophen shows positive cardioprotective effects In heart attack, arrhythmia

Long an under-studied yet widely-used over-the-counter medication, acetaminophen over the last few years is becoming recognized for a range of potential therapeutic uses beyond headache and pain.

16 Nov 2004

Heavy drinking after suffering a heart attack doubles risk of dying

Heavily drinking – or binging – even intermittently, almost doubles a person’s risk of dying after a heart attack, compared to that of a moderate drinker, according, to a first-of-its-kind study, reported at the American Heart Association’s Scientific Sessions 2004.

11 Nov 2004

Dementia patients receiving long-term treatment with Reminyl may be able to stay at home for longer compared

Shire Pharmaceuticals Group has announced that Dementia patients receiving long-term treatment with Reminyl (more than 36 months) may be able to stay at home for longer compared to those receiving treatment for shorter periods of time.

10 Nov 2004

Bretylium tosylate has unique benefits for patients with acute myocardial infarction

An "old" drug has unique benefits for patients with acute myocardial infarction (AMI; commonly known as heart attack), a finding that may contribute to a new understanding of how heart attacks develop, according to an article in the September/October American Journal of Therapeutics.

10 Nov 2004

Reviparin significantly reduces death and repeat heart attacks without increasing the risk of stroke

A major Canadian-led global study has found that an inexpensive anti-blood-clotting drug significantly reduces death and repeat heart attacks without increasing the risk of stroke.

8 Nov 2004

Early reports of thrombosis after insertion of drug-eluting stent

Authors of a research letter in this week’s issue of THE LANCET highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy.

21 Oct 2004

EMEA statement following withdrawal of Vioxx (rofecoxib)

EU regulators met with the marketing authorisation holder of Vioxx (rofecoxib), Merck Sharp & Dohme, on 4-5 October 2004 at the informal meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) held in Scheveningen, The Netherlands.

6 Oct 2004

Receiving a blood transfusion is associated with a greater risk of death for patients with acute coronary syndromes

The use of invasive procedures for treatment of ischemic heart disease has more than tripled in the past 2 decades and is likely to increase in high-risk patients, according to background information in the article.

5 Oct 2004